Cardio Diagnostics (NASDAQ:CDIO – Get Free Report) and Sutro Biopharma (NASDAQ:STRO – Get Free Report) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their dividends, earnings, analyst recommendations, institutional ownership, risk, profitability and valuation.
Valuation and Earnings
This table compares Cardio Diagnostics and Sutro Biopharma”s gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Cardio Diagnostics | $10,000.00 | 552.04 | -$6.50 million | ($2.92) | -0.64 |
| Sutro Biopharma | $102.48 million | 3.42 | -$191.09 million | ($11.97) | -1.77 |
Volatility & Risk
Cardio Diagnostics has a beta of 2.27, meaning that its share price is 127% more volatile than the S&P 500. Comparatively, Sutro Biopharma has a beta of 1.55, meaning that its share price is 55% more volatile than the S&P 500.
Institutional & Insider Ownership
8.1% of Cardio Diagnostics shares are owned by institutional investors. Comparatively, 97.0% of Sutro Biopharma shares are owned by institutional investors. 9.0% of Cardio Diagnostics shares are owned by insiders. Comparatively, 1.8% of Sutro Biopharma shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
Analyst Recommendations
This is a summary of recent ratings and price targets for Cardio Diagnostics and Sutro Biopharma, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Cardio Diagnostics | 1 | 0 | 0 | 0 | 1.00 |
| Sutro Biopharma | 1 | 0 | 10 | 2 | 3.00 |
Sutro Biopharma has a consensus price target of $47.30, indicating a potential upside of 123.80%. Given Sutro Biopharma’s stronger consensus rating and higher possible upside, analysts plainly believe Sutro Biopharma is more favorable than Cardio Diagnostics.
Profitability
This table compares Cardio Diagnostics and Sutro Biopharma’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Cardio Diagnostics | -43,133.33% | -82.28% | -76.03% |
| Sutro Biopharma | -395.25% | N/A | -88.12% |
Summary
Sutro Biopharma beats Cardio Diagnostics on 8 of the 15 factors compared between the two stocks.
About Cardio Diagnostics
Cardio Diagnostics Holdings, Inc. develops and commercializes epigenetics-based clinical tests for cardiovascular disease. It offers Epi+Gen CHD, a three-year symptomatic coronary heart disease (CHD) risk assessment test targeting CHD events, including heart attacks; and PrecisionCHD, an integrated epigenetic-genetic blood test for the early detection of coronary heart disease. Cardio Diagnostics Holdings, Inc. was founded in 2017 and is headquartered in Chicago, Illinois.
About Sutro Biopharma
Sutro Biopharma, Inc. operates as a clinical-stage oncology company. The company develops site-specific and novel-format antibody drug conjugates (ADCs) that enables its proprietary integrated cell-free protein synthesis platform, XpressCF and XpressCF+. Its product candidates include STRO-002, an ADC directed against folate receptor-alpha, which is in Phase II/III clinical trials for patients with ovarian and endometrial cancers; VAX-24 and Vax-31 pneumococcal conjugate vaccine candidates that is in Phase II/III clinical trials for the treatment of invasive pneumococcal disease; and MK-1484, a distinct cytokine derivative molecule that is in Phase I clinical study for the treatment of cancer. The company's pre-clinical product candidates include STRO-003, an ADC directed against an anti-receptor tyrosine kinase-like orphan receptor 1 (ROR1) for the treatment of solid tumors and hematological cancers; and STRO-004, a tissue factor (TF) targeting ADC for the treatment of TF-expressing solid tumors, including cervical, lung, and breast cancer. Sutro Biopharma, Inc. has collaboration and license agreements with Merck Sharp & Dohme Corporation to develop research programs focusing on cytokine derivatives for cancer and autoimmune disorders; Vaxcyte to discover and develop vaccine candidates for the treatment or prophylaxis of infectious diseases; Tasly Biopharmaceuticals Co., Ltd. to develop and commercialize STRO-002 in Greater China; EMD Serono to develop ADCs for multiple cancer targets; and Astellas Pharma Inc. to develop immunostimulatory ADC. The company was formerly known as Fundamental Applied Biology, Inc. Sutro Biopharma, Inc. was incorporated in 2003 and is headquartered in South San Francisco, California.
Receive News & Ratings for Cardio Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cardio Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.
